Fig. 6
Analysis of Tumor Microenvironment Molecular Characteristics in High and Low GloMICS Patients. (A) Distribution of TME immune cell type signatures between patients with high and low GloMICS levels. (B) Distribution of immune suppression signatures among high and low GloMICS groups. (C) Distribution of immune exclusion signatures among high and low GloMICS groups. (D) Differences in immunotherapy biomarkers between high and low GloMICS patients. (E) Distribution of Tumor Mutation Burden (TMB) between high and low GloMICS groups. (F) Distribution of Tumor Neoantigen Burden (TNB) between high and low GloMICS groups. (G) Distribution of M1 macrophages in high and low GloMICS groups. (H) The relationship between GloMICS levels and CD8 T cells. (I–K) Survival analysis combining GloMICS with TMB, TNB, and CD8 T cell indicators.
